丹納赫第一季超出預期，在經濟動盪中表現出韌性

丹納赫公司（NYSE：DHR）公佈了強勁的第一季業績，超出了分析師的每股收益和收入預期。儘管營收年減 2.5% 至 58 億美元，但丹納赫調整後每股收益為 1.92 美元，展示了營運效率和成本管理有效性。該公司領先的產品組合和業務系統的執行為持續的業績做出了貢獻。然而，丹納赫預計經濟環境充滿挑戰，預計第二季非公認會計準則核心收入將出現中個位數下降，反映出其謹慎的前景。

Danaher Surges Past Q1 Expectations, Demonstrating Resilience Amidst Economic Headwinds

丹納赫第一季業績大幅超越預期，在經濟逆風中展現韌性

New York, April 2024 - Danaher Corporation (NYSE: DHR), a global behemoth in life sciences and diagnostics, has unveiled its financial performance for the first quarter of 2024, defying expectations and showcasing its unwavering strength.

紐約，2024 年4 月- 全球生命科學和診斷領域的巨頭丹納赫公司（紐約證券交易所股票代碼：DHR）公佈了2024 年第一季的財務業績，超出預期，展示了其堅定不移的實力。

Despite a tumultuous economic climate, Danaher recorded a net income of $1.1 billion, translating to $1.45 per diluted common share. Notably, its non-GAAP diluted net earnings per common share reached $1.92 on an adjusted basis, far exceeding analysts' projections.

儘管經濟環境動盪，但丹納赫仍實現淨利 11 億美元，相當於每股稀釋普通股 1.45 美元。值得注意的是，其調整後的非公認會計原則稀釋後每股普通股淨利達1.92美元，遠遠超出分析師的預測。

Even as reported revenue dipped by 2.5% year-over-year to $5.8 billion, Danaher's operational prowess shone through. Non-GAAP core revenue experienced a modest 4.0% reduction, underscoring the company's ability to navigate challenging market conditions.

儘管報告收入年減 2.5% 至 58 億美元，但丹納赫的營運實力依然閃耀。非 GAAP 核心收入小幅下降 4.0%，突顯該公司應對充滿挑戰的市場環境的能力。

Operating cash flow remained robust at $1.7 billion, while non-GAAP free cash flow surged to $1.4 billion, providing ample liquidity for strategic investments and shareholder returns.

營運現金流保持強勁，達到 17 億美元，而非 GAAP 自由現金流飆升至 14 億美元，為策略投資和股東回報提供充足的流動性。

Rainer M. Blair, President and CEO of Danaher, hailed the quarter's achievements, highlighting the positive trends in the bioprocessing business and market share gains in Cepheid's molecular diagnostics division. He attributed these successes to the company's leading portfolio and the meticulous execution of the Danaher Business System, which he believes will continue to drive long-term growth and meaningful contributions to healthcare.

丹納赫總裁兼執行長 Rainer M. Blair 對本季的成就表示讚賞，強調了生物加工業務的積極趨勢以及 Cepheid 分子診斷部門的市場份額成長。他將這些成功歸功於公司領先的產品組合和丹納赫業務系統的精心執行，他相信這將繼續推動長期成長並為醫療保健做出有意義的貢獻。

Analysts Outpaced, Danaher's Execution Impresses

丹納赫的執行力令人印象深刻，分析師領先

Analysts had cautiously predicted earnings per share (EPS) of $1.72 and revenue of $5.62 billion for the quarter. However, Danaher's adjusted EPS of $1.92 handily surpassed these expectations, demonstrating the company's operational efficiency and ability to generate higher-than-anticipated profitability. Similarly, the reported revenue of $5.8 billion exceeded market forecasts, signaling robust sales performance across its diversified portfolio.

分析師謹慎預測本季每股盈餘 (EPS) 為 1.72 美元，營收為 56.2 億美元。然而，丹納赫調整後每股收益 1.92 美元輕鬆超出了這些預期，證明了該公司的營運效率和產生高於預期盈利能力的能力。同樣，報告的 58 億美元收入超出了市場預期，顯示其多元化產品組合的銷售業績強勁。

These results underscore Danaher's adaptability and strategic focus amidst intense competition and economic uncertainty. The company's ability to deliver exceptional financial outcomes is a testament to its strong business segments and effective cost management.

這些結果凸顯了丹納赫在激烈的競爭和經濟不確定性中的適應性和戰略重點。該公司提供卓越財務成果的能力證明了其強大的業務部門和有效的成本管理。

Cautious Guidance for Q2, Reflecting Global Economic Challenges

第二季謹慎指引，反映全球經濟挑戰

While Danaher's Q1 performance was commendable, the company adopted a more conservative tone when guiding for the second quarter and full year 2024. Acknowledging the persistent global economic uncertainty, the company anticipates a mid-single-digit decline in non-GAAP core revenue year over year for Q2 and a low-single-digit decline for the full year.

儘管丹納赫第一季的業績值得稱讚，但該公司在預測第二季和2024 年全年時採取了更保守的基調。營收年減中個位數下降第二季年減，全年年減個位數。

This guidance suggests that Danaher remains vigilant about potential market volatility and is prudently planning for the challenges that may lie ahead in the global economic landscape. Nonetheless, the company's strong foundation and proven track record of execution provide investors with confidence in its ability to weather any storms and emerge even stronger.

該指引表明，丹納赫對潛在的市場波動保持警惕，並正在謹慎規劃全球經濟格局中可能面臨的挑戰。儘管如此，該公司堅實的基礎和良好的執行記錄讓投資者對其抵禦任何風暴並變得更加強大的能力充滿信心。